Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Diagnostics
HPV genotyping can benefit clinical practice, study concludes
August 25th, 2005
A study published in the current issue of the Journal of the National Cancer Institute (JNCI) concludes that genotyping of specific high-risk types of the human papillomavirus (HPV), the cause of virtually all cases of cervical cancer, can benefit clinical practice by enabling more focused attention on women who are at highest risk, announced Digene Corp. (DIGE). According to the company, in the study the authors note they recently examined the performance of the Digene HPV Test and found the test demonstrated superior sensitivity and negative predictive value compared with a single Pap smear. The authors added that with separate, follow-up, typing of HPV...
Source: Women's Health Weekly (2005-08-25)
|
